Baicalin attenuates laser-induced choroidal neovascularization

Current Eye Research

Volumn 39, Issue 7, 2014, Pages 745-751

  Yang, Sung Jae ^a   Jo, Hyoung ^b   Kim, June Gone ^a   Jung, Sang Hoon ^b  

^a University of Ulsan   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

Author keywords

Age related macular degeneration; Baicalin; Choroidal neovascularization; Fluorescein angiography; VEGF

Indexed keywords

ANGIOGENIC FACTOR; BAICALIN; BEVACIZUMAB; GELATINASE A; PLATELET DERIVED GROWTH FACTOR; VASCULOTROPIN; BETA GLUCURONIDASE; FLAVONOID; NONSTEROID ANTIINFLAMMATORY AGENT; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FLUORESCENCE ANGIOGRAPHY; LASER COAGULATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBRETINAL NEOVASCULARIZATION; SURGICAL MICROSCOPE; UPREGULATION; VITREOUS BODY; ANIMAL; ANTAGONISTS AND INHIBITORS; BROWN NORWAY RAT; CHOROID; CHOROIDAL NEOVASCULARIZATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; EYE FUNDUS; INTRAVITREAL DRUG ADMINISTRATION; LASER; METABOLISM; PATHOLOGY; RADIATION RESPONSE; TREATMENT OUTCOME; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOTTING, WESTERN; CHOROID; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONOIDS; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; GLUCURONIDASE; INTRAVITREAL INJECTIONS; LASERS; MALE; MATRIX METALLOPROTEINASE 2; PLATELET-DERIVED GROWTH FACTOR; RATS; RATS, INBRED BN; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84901855689     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2013.868908     Document Type: Article

References (43)

1. Congdon N, O'Colmain B, Klaver CC, Klein R, Munoz B, Friedman DS, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004;122:477-485.
2. Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 1998;43: 245-269.
3. Zhang K, Zhang L, Weinreb RN. Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat Rev Drug Discov 2012;11: 541-559.
4. Rattner A, Nathans J. Macular degeneration: recent advances and therapeutic opportunities. Nat Rev Neurosci 2006;7:860-872.
5. Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1986;104:694-701.
6. The Moorfields Macular Study Group. Treatment of senile disciform macular degeneration: a single-blind randomised trial by argon laser photocoagulation. The Moorfields Macular Study Group. Br J Ophthalmol 1982; 66:745-753.
7. Kolar P, Vizdova D, Vlkova E. Photodynamic therapy with visudyne in treatment of wet form of age-related macular degeneration-two years results. Cas Lek Cesk 2006;145: 795-800.
8. Gragoudas ES, Adamis AP, Cunningham Jr ET, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
9. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
10. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
11. Amin R, Puklin JE, Frank RN. Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest Ophthalmol Vis Sci 1994;35: 3178-3188.
12. Higgins GT, Wang JH, Dockery P, Cleary PE, Redmond HP. Induction of angiogenic cytokine expression in cultured RPE by ingestion of oxidized photoreceptor outer segments. Invest Ophthalmol Vis Sci 2003;44:1775-1782.
13. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 2001;20:705-732.
14. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003;110:1517-1525.
15. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger S, Luna S, et al. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. Retina 2003;23: 14-23.
16. Nozaki M, Raisler BJ, Sakurai E, Sarma JV, Barnum SR, Lambris JD, et al. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A 2006;103:2328-2333.
17. Rasmussen H, Chu KW, Campochiaro P, Gehlbach PL, Haller JA, Handa JT, et al. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther 2001;12: 2029-2032.
18. Cao Y, Cao R, Brakenhielm E. Antiangiogenic mechanisms of diet-derived polyphenols. J Nutr Biochem 2002;13: 380-390.
19. Mojzis J, Varinska L, Mojzisova G, Kostova I, Mirossay L. Antiangiogenic effects of flavonoids and chalcones. Pharmacol Res 2008;57:259-265.
20. Hayasaka S, Kodama T, Ohira A. Traditional Japanese herbal (kampo) medicines and treatment of ocular diseases: a review. Am J Chin Med 2012;40:887-904.
21. Nagaki Y, Hayasaka S, Kadoi C, Nakamura N, Hayasaka Y. Effects of scutellariae radix extract and its components (baicalein, baicalin, and wogonin) on the experimental elevation of aqueous flare in pigmented rabbits. Jpn J Ophthalmol 2001;45:216-220.
22. Zhou Y, Zhang J. Effects of baicalin and liquid extract of licorice on sorbitol level in red blood cells of diabetic rats. Zhongguo Zhong Yao Za Zhi 1990;15:433-435, 448.
23. Nakamura N, Hayasaka S, Zhang XY, Nagaki Y, Matsumoto M, Hayasaka Y, et al. Effects of baicalin, baicalein, and wogonin on interleukin-6 and interleukin-8 expression, and nuclear factor-kappab binding activities induced by interleukin-1beta in human retinal pigment epithelial cell line. Exp Eye Res 2003;77:195-202.
24. Jung SH, Kang KD, Ji D, Fawcett RJ, Safa R, Kamalden TA, et al. The flavonoid baicalin counteracts ischemic and oxidative insults to retinal cells and lipid peroxidation to brain membranes. Neurochem Int 2008;53:325-337.
25. Zhiyan J, Zhengzhong B, Liange J, Shujie Z, Kai D, Hao C, et al. Ocular pharmacokinetic study on baicalin in lens of rabbits following intragastric administration. Graefes Arch Clin Exp Ophthalmol 2010;248:59-63.
26. Liu JJ, Huang TS, Cheng WF, Lu FJ. Baicalein and baicalin are potent inhibitors of angiogenesis: inhibition of endothelial cell proliferation, migration and differentiation. Int J Cancer 2003;106:559-565.
27. Dobi ET, Puliafito CA, Destro M. A new model of experimental choroidal neovascularization in the rat. Arch Ophthalmol 1989;107:264-269.
28. Pan CK, Durairaj C, Kompella UB, Agwu O, Oliver SC, Quiroz-Mercado H, et al. Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model. J Ocul Pharmacol Ther 2011;27:219-224.
29. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, et al. Photodynamic therapy. J Natl Cancer Inst 1998;90:889-905.
30. Kim C, Yu HG, Sohn J. The anti-angiogenic effect of chlorogenic acid on choroidal neovascularization. Korean J Ophthalmol 2010;24:163-168.
31. de Jong PT. Age-related macular degeneration. N Engl J Med 2006;355:1474-1485.
32. Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995;72: 638-645.
33. Sato Y. Update on endogenous inhibitors of angiogenesis. Endothelium 2006;13:147-155.
34. Zakarija A, Soff G. Update on angiogenesis inhibitors. Curr Opin Oncol 2005;17:578-583.
35. Francis PJ, Hamon SC, Ott J, Weleber RG, Klein ML. Polymorphisms in C2, CFB and C3 are associated with progression to advanced age related macular degeneration associated with visual loss. J Med Genet 2009;46:300-307.
36. Lommatzsch A, Hermans P, Muller KD, Bornfeld N, Bird AC, Pauleikhoff D. Are low inflammatory reactions involved in exudative age-related macular degeneration? Morphological and immunhistochemical analysis of AMD associated with basal deposits. Graefes Arch Clin Exp Ophthalmol 2008;246:803-810.
37. Bhutto IA, Baba T, Merges C, Juriasinghani V, McLeod DS, Lutty GA. C-reactive protein and complement factor H in aged human eyes and eyes with age-related macular degeneration. Br J Ophthalmol 2011;95:1323-1330.
38. Ni Z, Hui P. Emerging pharmacologic therapies for wet age-related macular degeneration. Ophthalmologica 2009; 223:401-410.
39. Srinivas NR. Baicalin, an emerging multi-therapeutic agent: pharmacodynamics, pharmacokinetics, and considerations from drug development perspectives. Xenobiotica 2010;40:357-367.
40. 2-induced aqueous flare elevation in pigmented rabbits. Jpn J Ophthalmol 2003;47:249-253.
41. Mor F, Quintana FJ, Cohen IR. Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization. J Immunol 2004;172:4618-4623.
42. Ciulla TA, Criswell MH, Danis RP, Hill TE. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol 2001; 119:399-404.
43. Zambarakji HJ, Nakazawa T, Connolly E, Lane AM, Mallemadugula S, Kaplan M, et al. Dose-dependent effect of pitavastatin on VEGF and angiogenesis in a mouse model of choroidal neovascularization. Invest Ophthalmol Vis Sci 2006;47:2623-2631.